Melatonin (part5) on Thrombosis, Sepsis and Mortality Rate in COVID-19 Patients published in International Journal of Infectious Diseases 2021 (online) and 2022 (printed)
Authors' Conclusions: Adjuvant use of melatonin may help to reduce thrombosis, sepsis, and mortality in COVID-19 patients
Commentary by DrV:
1. The safety and effectiveness of this intervention helps us understand the recent attacks against melatonin by CNN and the A.M.A.
2. The dose of 10 mg is reasonable if not minimal for an acute illness. Note that this is the same dose used in infants with sepsis as I have discussed in my published antiviral protocol; obviously, dose-optimization studies need to be completed to determine the optimal dose for adults which is quite likely in the range of 40-500 mg rather than 3-10 mg.
Title: The Effect of Melatonin on Thrombosis, Sepsis and Mortality Rate in COVID-19 Patients
Journal: International Journal of Infectious Diseases 2021 (online) and 2022 (printed)
Methods: single-center, prospective, randomized clinical trial conducted from 1 December 2020 to 1 June 2021 in Iraq; patients were chosen by a blocked randomization design.
Patients: 158 patients with severe COVID-19: 82 in the melatonin group (who received 10 mg melatonin in addition to standard therapeutic care) and 76 in the control group (given standard therapeutic care only).
Criteria: thrombosis, sepsis, and mortality rate on days 5, 11, and 17
Results: “The intervention group consisted of 82 patients, while the control group consisted of 76 patients. In comparison to the control group, thrombosis and sepsis developed significantly less frequently (P < 0.05) in the melatonin group during the second week of infection, while mortality was significantly higher in the control group (P < 0.05).
Conclusions: Adjuvant use of melatonin may help to reduce thrombosis, sepsis, and mortality in COVID-19 patients.”
DrV’s Newsletter, Notes, Essays, Articles, Videos, and Book Chapters is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.